Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer

[1]  Y. Niu,et al.  Potential markers predicting distant metastasis in axillary node‐negative breast carcinoma , 2002, International journal of cancer.

[2]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[3]  H. Höfler,et al.  Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  H. Bozcuk,et al.  Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators , 2001, Breast Cancer Research and Treatment.

[5]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[6]  P. Ingrand,et al.  Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. , 2001, International journal of oncology.

[7]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P Royston,et al.  A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. , 2000, Statistics in medicine.

[9]  L. Skoog,et al.  The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. , 2000, European journal of cancer.

[10]  A. Krüger,et al.  Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer , 2000, The International journal of biological markers.

[11]  P Royston,et al.  The use of fractional polynomials to model continuous risk variables in epidemiology. , 1999, International journal of epidemiology.

[12]  H. Höfler,et al.  Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up , 1999, British Journal of Cancer.

[13]  A. Scorilas,et al.  Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M Schumacher,et al.  Modelling the effects of standard prognostic factors in node-positive breast cancer , 1999, British Journal of Cancer.

[15]  J. Foekens,et al.  Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients , 1999, British Journal of Cancer.

[16]  G. Gasparini.  Prognostic variables in node-negative and node-positive breast cancer - editorial , 1998, Breast Cancer Research and Treatment.

[17]  A. Scorilas,et al.  Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. , 1998, Anticancer research.

[18]  H. Höfler,et al.  Prognostic impact of tumor biological factors on survival in node-negative breast cancer. , 1998, Anticancer research.

[19]  G. Scambia,et al.  A META-ANALYSIS , 2005 .

[20]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[22]  K. Chang,et al.  Prognostic significance of immunohistochemical analysis of cathepsin D in low‐stage breast cancer , 1993, Cancer.

[23]  P. Rouanet,et al.  A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol , 1993, Cancer.

[24]  Z. Shao,et al.  Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. , 1992, Cancer research.

[25]  M. Héry,et al.  Prognostic value of total cathepsin D in breast tumors , 1991, Breast Cancer Research and Treatment.

[26]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[27]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[28]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[29]  R. Tibshirani,et al.  Generalized additive models for medical research , 1995, Statistical methods in medical research.

[30]  P. Hall,et al.  Prognostic and predictive factors. , 2004, Methods in molecular medicine.

[31]  Douglas G. Altman,et al.  Methodological challenges in the evaluation of prognostic factors in breast cancer , 2004, Breast Cancer Research and Treatment.

[32]  J. Schneider,et al.  Histological Grade in Breast Cancer: Association with Clinical and Biological Features in a Series of 229 Patients , 2001, The International journal of biological markers.

[33]  N. Kayani,et al.  Immunohistochemical cathepsin-D expression in breast cancer: correlation with established pathological parameters and survival. , 2001, Pathology, research and practice.

[34]  Stefan Sperlich,et al.  Generalized Additive Models , 2014 .

[35]  G. Gasparini.  Prognostic variables in node-negative and node-positive breast cancer , 1998, Springer US.

[36]  F. May,et al.  Cathepsin D and breast cancer. , 1996, European journal of cancer.

[37]  T. Visakorpi,et al.  Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Maudelonde,et al.  The Lancet: saturday 11 November 1989 , 1989 .

[39]  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.